USPTO Examiner CHEN STACY BROWN - Art Unit 1648

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17135525FILOVIRUS ANTIBODYDecember 2020August 2023Abandon3110NoNo
16973471IMMUNOGENIC COMPOSITIONDecember 2020April 2024Allow4011YesNo
17114773Mutated Immunoglobulin-Binding PolypeptidesDecember 2020March 2024Allow3921YesNo
17092164HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTIONNovember 2020May 2021Allow720YesNo
17087704Stabilized Coronavirus Spike (S) Protein Immunogens and Related VaccinesNovember 2020October 2023Allow3521YesNo
17052470ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTIONNovember 2020May 2024Allow4211YesNo
17066874COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTIONOctober 2020September 2023Allow3611YesNo
17041790HUMAN WEST NILE VIRUS ANTIBODIES AND METHODS OF USE THEREFORSeptember 2020February 2024Allow4121YesNo
16982036VACCINE COMPOSITIONSSeptember 2020June 2024Abandon4511NoNo
17019825Stabilized Coronavirus Spike (S) Protein Immunogens and Related VaccinesSeptember 2020November 2020Allow200YesNo
17009448DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1,2,3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1,2,3, AND 4September 2020April 2023Allow3210NoNo
16971284Aluminum Oxide Surfaces and Interface MoleculesAugust 2020April 2024Allow4411YesNo
16995439MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETESAugust 2020February 2023Allow3020NoNo
16994500INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTIONAugust 2020July 2023Allow3511NoNo
16989796HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTIONAugust 2020February 2022Abandon1851YesYes
16989038PARAINFLUENZA VIRUS 5 BASED VACCINESAugust 2020September 2022Allow2510YesNo
16938105Engineered HCV E2 Immunogens and Related Vaccine CompositionsJuly 2020March 2021Allow811YesNo
16935121NOVEL AAV MEDIATED INFLUENZA VACCINESJuly 2020January 2023Abandon3001NoNo
16927169ANTI-RSV MONOCLONAL ANTIBODY FORMULATIONJuly 2020January 2023Allow3111YesNo
16924032COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR INFLUENZAJuly 2020November 2022Abandon2810NoNo
16922322EPSTEIN-BARR VIRUS VACCINESJuly 2020January 2024Allow4321YesYes
16959828POLYNUCLEOTIDES ENCODING ANTI-CHIKUNGUNYA VIRUS ANTIBODIESJuly 2020June 2023Allow3510NoNo
16946708ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOFJuly 2020November 2022Abandon2810NoNo
16914829RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEMJune 2020August 2022Abandon2501NoNo
16911511Separation MethodJune 2020December 2022Allow3020NoNo
16909313NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONSJune 2020September 2022Allow2711YesNo
16906373METHOD FOR THE QUANTIFICATION OF MEASLES AND RUBELLA TARGETSJune 2020June 2023Abandon3610NoNo
16904793RSV-SPECIFIC BINDING MOLECULEJune 2020May 2022Abandon2311NoNo
16901410TRUNCATED ROTAVIRUS VP4 PROTEIN AND APPLICATION THEREOFJune 2020March 2022Allow2100YesNo
16772131FLAVIVIRUS VACCINEJune 2020September 2023Allow3941YesNo
16896991MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJune 2020September 2021Allow1600YesNo
16896980MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJune 2020September 2021Allow1600YesNo
16897013MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJune 2020April 2022Allow2210YesNo
16897001MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJune 2020November 2021Allow1700YesNo
16897027MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJune 2020April 2022Allow2210YesNo
16768550METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODSMay 2020August 2023Abandon3921NoNo
16768499ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAMEMay 2020August 2023Allow3840YesNo
16768402SAPONIN PURIFICATIONMay 2020October 2022Allow2910YesNo
16767737NOVEL METHODS OF VACCINATION USING ICOSAHEDRAL PHAGEMay 2020October 2022Abandon2911YesNo
16884475Separation MethodMay 2020May 2022Allow2411YesNo
15931787COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCERMay 2020February 2022Allow2121YesNo
16763013Compositions And Methods for Enhancing Production, Growth, Spread, or Oncolytic and Immunotherapeutic Efficacy of Interferon-Sensitive VirusesMay 2020November 2023Allow4221YesNo
16762836RECOMBINANT VECTORS ENCODING ZIKA VIRUS PROTEIN SUBUNITSMay 2020April 2023Allow3520NoNo
16864566HUMAN CYTOMEGALOVIRUS VACCINEMay 2020August 2021Allow1500YesNo
16855046Risk Stratification for Contagious DiseaseApril 2020August 2021Abandon1520YesNo
16753018GENE THERAPIES FOR LYSOSOMAL DISORDERSApril 2020July 2023Allow4011YesNo
16652705CHIMERIC YELLOW FEVER ZIKA VIRUS STRAINApril 2020February 2022Allow2310YesNo
16652902Compositions for Booster Vaccination Against DengueApril 2020February 2023Allow3440YesNo
16651061MUTATED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR CHEMICAL COUPLING OF LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BINDING AND PRODUCTION METHOD THEREOFMarch 2020May 2023Allow3711YesNo
16826529VACCINE DEVELOPMENT METHODOLOGY BASED ON AN ADHESION MOLECULEMarch 2020October 2022Abandon3110NoNo
16649567TOBAMOVIRUS-BASED VIRUS-LIKE PARTICLES AND VACCINESMarch 2020November 2021Allow2011YesNo
16820462ALPHAVIRUS AND COMPOSITIONS, METHODS, AND KITS RELATED THERETOMarch 2020April 2022Allow2511YesNo
16813179METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUSMarch 2020July 2022Abandon2910NoNo
16645788Mammal-specific Growth-defective ArbovirusMarch 2020May 2024Allow5031NoYes
16645417FILOVIRUS VACCINES AND METHODS OF USEMarch 2020December 2021Abandon2111NoNo
16803937DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSEFebruary 2020February 2023Allow3530NoNo
16794854LENTIVIRAL VECTOR-BASED JAPANESE ENCEPHALITIS IMMUNOGENIC COMPOSITIONFebruary 2020August 2023Allow4140YesNo
16790289ANTI-DENGUE VIRUS ANTIBODIES AND USES THEREOFFebruary 2020November 2022Abandon3321NoNo
16788182HMPV/HPIV3 MRNA VACCINE COMPOSITIONFebruary 2020February 2022Allow2410NoNo
16781782LIQUID FLOURESCENT DYE CONCENTRATE FOR FLOW CYTOMETRY EVALUATION OF VIRUS-SIZE PARTICLES AND RELATED PRODUCTS AND METHODSFebruary 2020February 2023Allow3711YesNo
16779807UTILITIES OF STIMULATED WHOLE BLOOD CULTURE SYSTEMSFebruary 2020November 2023Allow4531NoNo
16636094COMPOSITIONS AND METHODS FOR DELIVERY OF AAVFebruary 2020July 2022Allow2900YesNo
16745986DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPESJanuary 2020June 2021Allow1700NoNo
16631557CHIKUNGUNYA VIRUS ANTIGEN CONSTRUCTSJanuary 2020January 2023Allow3611NoNo
16743415AAV CAPSID PRODUCTION IN INSECT CELLSJanuary 2020January 2023Allow3601NoNo
16629339TREATMENT OF SPINAL MUSCULAR ATROPHYJanuary 2020July 2022Allow3010NoNo
16628057A SYNTHETIC POLYPEPTIDE EPITOPE BASED VACCINE COMPOSITIONJanuary 2020January 2022Allow2400YesNo
16722393THERMAL INACTIVATION OF ROTAVIRUSDecember 2019April 2021Allow1600YesNo
16623026COMPOSITIONS AND ADMINISTRATION OF CHIMERIC GLYCOPROTEIN LYSSAVIRUS VACCINES FOR COVERAGE AGAINST RABIESDecember 2019June 2022Allow3021YesNo
16714370COMPOSITIONS AND METHODS FOR CANCER THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLSDecember 2019March 2022Abandon2720NoNo
16708797Recombinant Antigen Derived From Zika Virus E Protein And Use ThereofDecember 2019December 2021Allow2411YesNo
16707961Methods for Culturing and for Detecting Stealth Adapted VirusesDecember 2019May 2022Abandon2901NoNo
16620581Zika Virus Like Particle (VLP) Based Vaccine and Microneutralization AssayDecember 2019November 2021Allow2321YesNo
16692488METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSESNovember 2019August 2021Allow2010NoNo
16615652EXPRESSION VECTORS AND RELATED METHODS OF DELIVERY OF Na/K ATPASE/Src RECEPTOR COMPLEX ANTAGONISTSNovember 2019July 2024Abandon5531YesNo
16612221TARGETED PREVENTION OF MATERNAL TO FOETAL VERTICAL TRANSMISSION OF INFECTIONNovember 2019January 2023Allow3931YesNo
16612352ALPHAVIRUS NEOANTIGEN VECTORSNovember 2019January 2022Allow2711YesNo
16611786RECOMBINANT MEASLES VACCINE EXPRESSING HTERTNovember 2019January 2022Allow2710NoNo
16672168HUMAN ROTAVIRUS STRAINS AND VACCINESNovember 2019March 2021Allow1600YesNo
16669401COMPOSITIONS AND METHODS FOR PRODUCTION OF COLD-CHAIN VACCINESOctober 2019January 2022Abandon2711NoNo
16665708T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLAOctober 2019July 2021Allow2001YesNo
16594763Devices, Systems, and Methods for Aiding in the Detection of a Physiological AbnormalityOctober 2019November 2022Allow3750YesNo
16595288METHODS AND COMPOSITIONS FOR ACTIVATION OF INNATE IMMUNE RESPONSES THROUGH RIG-I LIKE RECEPTOR SIGNALINGOctober 2019January 2022Allow2720YesNo
16589751STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDESOctober 2019February 2021Allow1600NoNo
16589601VACCINE AGAINST RSVOctober 2019July 2021Allow2110YesNo
16497574CHIMERIC INSECT-SPECIFIC FLAVIVIRUSESSeptember 2019August 2022Allow3421YesNo
16578748RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USESeptember 2019January 2021Allow1600YesNo
16566542IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN ANTIBODY AGAINST RSV PREFUSION F PROTEINSeptember 2019September 2021Allow2520YesNo
16561755Compositions and Methods for Dengue Virus Chimeric Constructs in VaccinesSeptember 2019October 2021Abandon2511NoNo
16555912METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENTAugust 2019August 2021Abandon2310NoNo
16553213COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSISAugust 2019April 2022Abandon3121YesNo
16548309Multi-Specific Antibodies for Cross-Neutralization of Multiple Filovirus GlycoproteinsAugust 2019June 2021Allow2110NoNo
16545777METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTAugust 2019November 2019Allow200YesNo
16542742METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTAugust 2019October 2019Allow200YesNo
16602348Methods for assessing risk of developing a viral of disease using a genetic testAugust 2019October 2020Allow1401YesNo
16536531Anti-Zika Virus Antibodies and Methods of UseAugust 2019May 2021Allow2110NoNo
16528710IMMUNOASSAY USING AT LEAST TWO PEGYLATED ANALYTE-SPECIFIC BINDING AGENTSAugust 2019April 2021Allow2011YesNo
16523802MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINESJuly 2019July 2022Abandon3621NoNo
16480671VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOFJuly 2019April 2024Allow5741YesNo
16513263MATERIALS AND METHODS FOR PRODUCING IMPROVED LENTIVIRAL VECTOR PARTICLESJuly 2019December 2020Allow1700YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, STACY BROWN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
16
Examiner Affirmed
12
(75.0%)
Examiner Reversed
4
(25.0%)
Reversal Percentile
38.2%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
130
Allowed After Appeal Filing
18
(13.8%)
Not Allowed After Appeal Filing
112
(86.2%)
Filing Benefit Percentile
17.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CHEN, STACY BROWN - Prosecution Strategy Guide

Executive Summary

Examiner CHEN, STACY BROWN works in Art Unit 1648 and has examined 976 patent applications in our dataset. With an allowance rate of 51.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner CHEN, STACY BROWN's allowance rate of 51.1% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHEN, STACY BROWN receive 2.08 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +55.3% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.8% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.8% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 87.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 74.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 65.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.0% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.